Stereotactic radiosurgery

General Neurology

Updated 07.11.2024
Released 04.22.2005
Expires For CME 07.11.2027

Stereotactic radiosurgery

Authors: Jason A Heth MD, Lisa M Walsh BS, Katherine Holste MD

See Contributor Disclosures

Editor: Matthew Lorincz MD PhD

Stereotactic radiosurgery

In This Article

Quick Link

Introduction

Overview

Stereotactic radiosurgery is the precise delivery of a lethal dose of radiation to a target while minimizing the radiation exposure of the surrounding tissues. This review discusses the five techniques of stereotactic radiosurgery: linear accelerator (LINAC)-based stereotactic radiosurgery, Gamma Knife, tomotherapy, robotic mini-linear accelerator (CyberKnife®), and heavy particle or proton beam stereotactic radiosurgery. The major indications for stereotactic radiosurgery for neurosurgical conditions include metastatic brain and spine tumors, primary brain tumors (eg, meningioma, vestibular schwannoma), arteriovenous malformations, and trigeminal neuralgia, and, more rarely, movement disorders, certain types of intractable epilepsy, and psychiatric disorders such as severe depression. The incorporation of real-time patient movement tracking (CyberKnife) allowed for the extension of stereotactic radiosurgery into the treatment of spinal disease as well as non-nervous system conditions, such as lung and prostate cancer. Stereotactic radiosurgery has assumed a significant role, both as the primary modality and in conjunction with surgery or chemotherapy, in treating a wide variety of disorders both within and outside the central nervous system.

Key points

	• Stereotactic radiosurgery is the precise application of a lethal dose of radiation to a localized lesion while exposing nearby normal tissue to a sublethal dose.
	• There are five primary techniques for stereotactic radiosurgery delivery: Gamma Knife, LINAC, tomotherapy, CyberKnife®, and heavy particle (proton beam).
	• Radiosurgery is used to treat a variety of pathologies, including brain and spine metastases, vestibular schwannomas, pituitary adenomas, primary central nervous system neoplasms, vascular lesions, including arteriovenous malformations, and functional disorders such tremor, epilepsy, and trigeminal neuralgia.

Historical note and terminology

Stereotactic radiosurgery is the precise application of a lethal dose of radiation to a localized lesion while exposing nearby normal tissue to a sublethal dose. If this radiation is fractionated, the same precise deposition of radiation is delivered over several sessions, allowing for a greater total dose to the target tissue and protection of the surrounding normal structures. The principles underlying stereotactic radiosurgery have been understood for decades, but advances in stereotactic techniques, high-resolution imaging, and computer processing have established stereotactic radiosurgery as a standard neurosurgical technique.

The use of radiation to treat disease is based on the Compton effect, where the collision of a photon with an atom creates free radicals that stop cell cycle replication or cause cell death (165). Medical use of radiation for therapy began in 1922 when Coutard and Hautant treated a case of laryngeal carcinoma with radiation therapy (38). In 1934, Coutard described the concept of fractionation: the total dose of radiation is divided into multiple smaller doses allowing for recovery of normal tissue, repopulation of tumor cells, reoxygenation of tumor cells to increase radiosensitivity, and reassortment of tumor cells within the cell cycle (60). However, low-energy emission radiation from early machines made tissue penetration inadequate for anything but superficial lesions. High-voltage machines were later developed, producing radiation with energy levels of several million electron volts that could be used to treat intracranial neoplasms. These devices were ultimately replaced by cobalt 60 units and linear accelerators in the modern era as sources for high-voltage x-rays (25).

In the 1930s, heavy particles were first used by Lawrence and associates at the University of California, Berkeley, to irradiate small volumes of normal and pathologic tissues (94). The Berkeley cyclotron permitted the use of high-energy alpha particles and proton and deuteron beams to treat deeper brain tissue volumes using the "Bragg peak" rotation technique (166).

Leksell created stereotactic radiosurgery in the early 1950s by combining a stereotactic frame with an orthovoltage x-ray tube (100). He later developed the Gamma Knife using 201 cobalt 60 sources. The early Swedish experience with stereotactic radiosurgery for cerebral arteriovenous malformations led to Gamma Knife centers around the world as additional therapeutic applications were developed. The University of Pittsburgh became the site of the first cobalt 60 Gamma Knife unit for clinical use in North America in 1987. The Gamma Knife improved radiation therapy by providing accelerated treatment times and improved conformation of the radiation dose to the shape of the lesion.

By 1987, Winston and Lutz had modified their linear accelerator in Boston to treat neurosurgical patients (182). Available as standard equipment in many radiation therapy departments, only minor modifications were required to convert a standard LINAC to suitability for stereotactic radiosurgery. Ease of fractionation, unlimited field size, and photon delivery flexibility to treat nonspherical lesions were major advantages to this system. Stereotactic radiosurgery requires extensive quality assurance procedures to maintain safety and reliability of radiation dosage and targeting (25).

Linear accelerator stereotactic radiosurgery offered four major advances:

(1) A stereotactic system with a movable isocenter.
(2) A secondary collimator system that focused the radiation beams to the narrowest possible peripheral penumbra.
(3) A patient couch that spared body irradiation.
(4) A computerized program that targeted the high-energy photon beams.

Commonly used stereotactic radiosurgery systems are the Gamma Knife and the LINAC. Both utilize rigid fixation of a stereotactic head frame to the patient for optimal spatial accuracy, which is uncomfortable for the patient, is time consuming for the stereotactic radiosurgery team, and makes fractionation difficult. The Leksell Gamma Knife systems feature 192 cobalt 60 sources arranged in a cone section configuration with enhanced flexibility in number and diameters of beams intersecting at isocenters compared with previous systems. This allows for treatment of multiple intracranial lesions within a single-session frame placement with submillimeter accuracy (149; 185).

The newest Leksell Gamma Knife system, approved by the United States Food and Drug Administration in August 2016, uses a cone beam computed tomography scanner in addition to an infrared camera to perform Gamma Knife radiosurgery using the thermal plastic mask head immobilization, which is standard for external beam radiation (185; 176). Use of the thermal plastic mask also allows for multiple sessions to be performed without having to apply and reapply a stereotactic frame. One large study of 100 patients who underwent frameless Gamma Knife radiosurgery demonstrated two major improvements: improved workflow and increased number of patients eligible for Gamma Knife due to fractionation. The accuracy of the frameless system is preserved with submillimeter accuracy (176). Both the stereotactic head frame and thermal plastic mask are used today, and they both offer their own set of advantages and disadvantages for each patient. The use of Gamma Knife has increased rapidly since its inception. A worldwide survey-based study suggested that there appears to be worldwide consensus on its use for meningiomas, metastatic tumors, and arteriovenous malformations; more treatment variation exists for craniopharyngiomas and pituitary tumors (61).

Frameless stereotactic radiosurgery performed on a LINAC system uses optical tracking systems. These systems have a reproducible accuracy of less than 1.0 mm (146). A newer method of LINAC-based radiosurgery known as volumetric arc therapy (VMAT or RapidArc®) delivers radiation in a gantry arc motion, which allows adjustments to both beam dose rate and gantry speed to further customize conformal dose distribution (125). Delivering treatment in this fashion with continuous gantry rotation allows for treatment of multiple intracranial lesions with a few or even a single isocenter set-up and, most importantly, reduces treatment times to 5 to 10 minutes per lesion while maintaining spatial accuracy of less than 1 mm (178; 09).

The CyberKnife® combines a lightweight (130 kg) 6 MeV linear accelerator with a highly maneuverable, articulated robotic arm to position and aim the LINAC. This system improved ease of fractionation, allowed for treatment of young patients without general anesthesia, and had the ability to treat lesions throughout the body. By utilizing real-time image guidance, the need for skeletal fixation for positioning or rigid immobilization of the patient was eliminated. The multiple degrees of freedom afforded by the robotic arm unconstrained the treatment beam and could target nonisocentric beams to any point within the lesion. Maximizing conformation of the treatment beam to the shape of the lesion provided homogenous dosing (25). Treatment with the CyberKnife has proven effective, and with its spatial accuracy and dose homogeneity, it provided the option of stereotactic radiosurgery treatment to patients with lesions in close proximity to critical central nervous system structures.

Clinical aspects

Description

There are five primary techniques for stereotactic radiosurgery delivery: Gamma Knife, LINAC, tomotherapy, CyberKnife®, and heavy particle (proton beam) (52).

Gamma Knife. Gamma Knife radiosurgery typically involves placing the patient in a stereotactic frame, which is attached to the patient under local anesthesia by pins that penetrate the scalp into the outer table of the skull. The Gamma Knife focuses 192 cobalt 60 radiation sources, mounted in a 18,000 kg shield, through a collimated helmet on to a target 403 mm from the cobalt 60 radiation sources.

Leksell Gamma Knife Perfexion

State-of-the-art Gamma Knife, which uses 192 cobalt 60 radiation sources focused on the target. The patient’s head is fixed with a stereotactic frame. Treatment is limited to cranial and upper cervical lesions. (Figure courtesy of...

Collimation allows for creation of up to 192 16-, 8-, and 4-mm beams that can each be overlaid and blocked to conform to each isocenter. This independently moving sector design allows for significantly enhanced flexibility, which leads to shorter treatment times and the ability to treat multiple intracranial lesions with a single session and frame placement (150). The new Leksell Gamma Knife system, Icon, approved by the FDA in August 2016, uses a cone beam computed tomography scanner and infrared camera to perform Gamma Knife radiosurgery using the thermal plastic mask head immobilization, which is standard for external beam radiation (185; 176). Use of the thermal plastic mask also allows for multiple sessions to be performed without having to apply and reapply a stereotactic frame, which allows for fractionation of the radiation, increasing the number of patients eligible for Gamma Knife.

Linear accelerator

Schematic of a typical linear accelerator (LINAC) for radiation therapy that can be adapted for stereotactic radiosurgery. The gantry rotates as the radiation is delivered, thus, limiting the exposure to tissues other than the tar...

LINAC. LINAC utilizes high-energy photons in a series of converging arcs to focus radiation onto a specific target. The newest method of LINAC-based radiosurgery is volumetric arc therapy (VMAT). In VMAT therapy, the LINAC modulates the shape, dose rate, and energy of the exiting beams via a multileaf collimator while rotating continuously around the target. Adjustments can be made to the multileaf collimator, gantry rotation speed, and dose delivery rate, which allows for greater customization of the conformal dose distribution (125). This gives the VMAT the advantage of allowing highly conformal treatments to multiple intracranial lesions with reduced treatment times. New LINAC-based techniques have outputs as high as 1400 monitor units per minute and can complete a high-dose stereotactic treatment in less than 10 minutes. A study of VMAT for the treatment of multiple intracranial metastases has demonstrated effective 1- and 2-year local control rates (86.7% and 71.6% rates, respectively). The intracranial progression-free survival at 6 months and 1 year were 48.5% and 19.4%, respectively (05). In the case of multiple intracranial metastatic lesions, VMAT typically is performed by using multiple isocenters, one for each lesion. Alternative approaches for VMAT using multiple noncoplanar treatment arcs have been suggested as a method for reducing overall treatment time (145).

Tomotherapy. Tomotherapy uses a LINAC mounted within the gantry of a CT scanner, allowing for imaging just prior to treatment delivery (178). In this approach, a continuous, helical-shaped beam with a single isocenter is used to provide radiotherapy to an entire region. This appears to be advantageous as it can treat a large volume without multiple isocenters. Still, it unfortunately requires a longer treatment time (171). In previous studies, tomotherapy resulted in tumor control and a low incidence of toxicities when used as treatment for single or multiple brain metastases (123; 85). It was also found to be a safe treatment for brain metastases over 2 cm that could not be surgically removed.

CyberKnife. The CyberKnife system combines a lightweight LINAC optimized for stereotactic radiosurgery with an articulated highly maneuverable robotic arm.

Accuray CyberKnife® M6

A lightweight LINAC mounted on a robotic arm is continuously fed information regarding target movement (eg, respiration) in real-time by two orthogonal fluoroscopes. (Figure used with permission from Accuray Inc.)

The system uses image registration techniques from neuroimaging studies prior to treatment and combines them with radiographs of skeletal features associated with the treatment site obtained from two fixed diagnostic fluoroscopes mounted on either side of the patient. This information determines the treatment site, coordinates with respect to the CyberKnife LINAC, and actuates the robotic arm to accurately direct the beam to the treatment site. When the target moves (such as with respiration), the process detects the change and realigns the aim of the beam to the new coordinates in near real-time. This system obviates the need for rigid fixation, allows the treatment of lesions throughout the body, and allows for fractionation of treatment without recurrent patient discomfort (02). The flexibility of the CyberKnife has encouraged treatment of extracranial pathology, including spinal lesions and cancers of the liver, lung (41), prostate, and kidney (62).

Heavy particle (proton beam). The proton beam system employs the ionization portion of the Bragg peak, which describes deposition of radiation from heavy particle beams such as helium. Charged particles produce a triphasic pattern of radiation with an intermediate dose on entrance of the head and a narrow peak of high-dose radiation (Bragg ionization peak) that can be adjusted to target tissue penetration depth and a minimal exit dose. Although the need for a cyclotron limited proton therapy to only a few centers in the United States for many years, there are now many proton therapy centers. The added cost of refinements for improved accuracy, such as pencil beam scanning, as well as expected reductions in reimbursement for proton therapy, will make the financial viability of many proton therapy centers questionable in the future (46). However, as the cost of this technology lowers with time, there is an important role for proton beam, particularly in the treatment of pediatric patients due to a significantly lower rate of secondary malignancy when compared to photon-based treatments (35). In addition to several solid organ-based tissue cancers, promising results have also been obtained in treating challenging intracranial tumors, such as chordomas (155) and glioblastoma (121), and several trials and investigations are ongoing (120).

FLASH radiotherapy. FLASH radiotherapy is a new approach that has significant promise in the treatment of brain tumors. FLASH radiotherapy treatment provides irradiation at a singular high dose over 40 Gy/s, reducing radiation-induced damage in healthy tissues without reducing tumor treatment efficiency (104). Animal studies have found that FLASH RT can delay glioblastoma growth while also sparing learning and memory deficits typically induced by radiation (122). FLASH RT is currently gaining attention in the clinical realm. The first clinical trial for FLASH RT has been completed and concluded that FLASH RT resulted in mild toxic effects and therapeutic benefit in the treatment of symptomatic bone metastases (113). Additional animal studies and clinical trials must be completed before FLASH RT can be used in treating brain metastases, but this method has strong potential to improve the efficacy of stereotactic radiosurgery.

Although capable of treating lesions as small as 2 to 3 mm diameter, all Gamma Knife, LINAC, and proton beam–based techniques require accurate target localization preoperatively, typically with a contrast MRI for primary and metastatic brain tumors, and CT arteriography for arteriovenous malformations. Isodose plots are constructed from the neuroimaging studies to calculate dosimetry. Treatment planning is a team effort including a radiation oncologist, radiation physicist, and neurosurgeon. This effort is aided by advancements in computer programs that help to automate much of the treatment planning and delivery. Stereotactic radiosurgery treatment time varies from under 30 minutes to an hour or more, depending on the number of isocenters treated and the stereotactic radiosurgery technique (system) employed. The patient is usually discharged the same day or within 24 hours. Corticosteroids, antiemetics, or anticonvulsants may be administered.

The goal of stereotactic radiosurgery is the delivery of a lethal radiation dose to the target tissue without damage to the adjacent normal tissue. Most stereotactic radiosurgery devices have total clinical accuracy on the order of 1 to 1.5 mm.

Treatment goals depend on the type and location of the lesion treated. For certain benign tumors, eg, meningiomas and vestibular schwannomas, lesion stabilization may be sufficient; for most malignant tumors, especially symptomatic metastatic tumors, shrinkage or obliteration of the lesion may be necessary. Arteriovenous malformations and other vascular lesions usually require obliteration, which may take 2 years or more after treatment before the risk of bleeding is completely eliminated. For tumors, histological tissue diagnosis and determination of the lesion margins are essential. For functional disorders, notably trigeminal neuralgia and epilepsy, the goal is symptom improvement (143; 170).

Indications

Stereotactic radiosurgery was initially used for functional neurosurgery (eg, lesioning the thalamus for cancer pain) (99); functional neurosurgery indications have expanded to include trigeminal neuralgia, movement disorders such as Parkinson disease and essential tremor, epilepsy, and certain affective disorders (128; 86; 12). Current primary indications for stereotactic radiosurgery include malignant tumors (tumors metastatic to the brain or spine, malignant gliomas), benign tumors (meningiomas, vestibular schwannomas, and pituitary adenomas), and arteriovenous malformations.

The terms stereotactic radiosurgery and stereotactic body radiotherapy are often used interchangeably. However, stereotactic radiosurgery, as sanctioned by the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, and the American Society for Radiation Oncology, is strictly defined as the utilization of externally generated ionizing radiation to inactivate or eradicate defined target(s) in the head or spine (11) in one treatment fraction only. Stereotactic body radiotherapy is defined as the delivery of radiation to an extracranial target in multiple fractions, typically 2 to 5 (27). It operates under the same principles as stereotactic radiosurgery, with both practices using external beam radiotherapy with high precision and accuracy to deliver a biologically high radiation dose with locally curative intent (57). Stereotactic body radiotherapy is currently used to manage a wide array of disease sites, including oligometastases and spine, lung, prostate, liver, renal cell, pelvic, and head and neck tumors (109). For the treatment of oligometastases, stereotactic body radiosurgery can lead to high-dose irradiation of tumor sites, delaying the use of toxic systemic therapies and leading to longer survival without disease symptoms (21).

The Congress of Neurological Surgeons has updated its guidelines on the use of stereotactic radiosurgery for the treatment of adults with metastatic brain tumors (55). Although no level 1 evidence exists, stereotactic radiosurgery is recommended on the basis of level 3 evidence as an alternative to surgical resection in cases of solitary brain metastasis when surgery is likely to induce new neurologic deficits (55). If a metastatic brain lesion is treated with surgery, stereotactic radiosurgery is also indicated to reduce local recurrence rates (124). Results from clinical trials continue to support the use of stereotactic radiosurgery for patients with two to four brain metastases instead of whole-brain radiation therapy as long as their cumulative volume is less than 7 mL (55). Stereotactic radiosurgery alone also has been shown to improve median overall survival for patients with more than four metastases as long as the cumulative tumor volume is less than 7 mL (55). There is level 1 evidence, however, to demonstrate that in patients with two to three brain metastases not amenable to surgery, the addition of stereotactic radiosurgery to whole-brain radiation does not improve survival relative to whole-brain radiation therapy alone (07). Salvage stereotactic radiosurgery is not inferior to whole-brain radiation in patients with four or fewer brain metastases (80). Although not well studied in a controlled study, stereotactic radiosurgery for patients with 5 to 15 brain metastases has been shown to be well tolerated without an increase in toxicity, treatment failure, or need for salvage therapy (70). Patients with 10 or more brain metastases treated with LINAC radiosurgery also were able to maintain pretreatment neurocognitive function in the majority of cases (118).

There is also interest in using stereotactic radiosurgery preoperatively (144). This strategy has the theoretical advantage of preventing dissemination of tumor cells that may occur during surgery to prevent leptomeningeal spread. It also avoids the potential problem of defining residual disease postoperatively when image interpretation may be challenging. Preoperative radiosurgery has been associated with good local tumor control in retrospective studies. When preoperative radiosurgery was utilized for brain metastases, local control at 1 year was achieved in 84% to 91% of cases (08; 133; 172). Furthermore, in a multi-institutional study of preoperative radiosurgery for brain metastases, local recurrence rates at 1 and 2 years were found to be 15% and 17%, respectively. Median overall survival with preoperative radiosurgery was 16.9 to 17.2 months, with a 2-year overall survival rate of 36.7% to 38.4% when treated (140; 139). Rates of radiation necrosis and leptomeningeal disease were 5% and 4%, respectively (172). Histologically, brain metastases that were irradiated preoperatively were more likely to have evidence of tumor necrosis on resection than non-irradiated tumor, though there was no statistical association between the amount of tumor necrosis and the time interval from radiosurgery to surgery (89). When examining the rate of a composite endpoint of local failure, meningeal disease, and symptomatic radiation necrosis resulting from preoperative fractionated stereotactic radiation therapy, the composite endpoint event rate was 8% per patient, which is much lower than the reported composite rates after postoperative stereotactic radiosurgery (49% to 60%) (131).

These results indicate that preoperative radiosurgery may decrease the risk of leptomeningeal disease and radiation necrosis. Preoperative radiosurgery has the potential to become an effective treatment strategy, but it requires further investigation. Two additional studies are currently in progress to study the outcomes of using preoperative stereotactic radiation therapy for brain metastasis (53; 39).

Postoperative radiosurgery is conventionally used in the treatment of both brain and spinal metastases. The International Stereotactic Radiosurgery Society recommends stereotactic radiosurgery as a first-line treatment for postoperative brain metastases resection cavities, with a meta-analysis of 13 studies finding a median local control rate of 80.5% and improved neurocognitive outcomes versus whole-brain radiation therapy (141). Local recurrence rates increase with subtotal resection, larger treatment volume, lower margin dose, and a greater than 3-week delay between surgery and stereotactic radiosurgery (110). Fractionated radiotherapy may be more effective in patients with large tumor cavity volumes or diameters and a preoperative diameter greater than 2.5 cm (141). Postoperative stereotactic body radiotherapy is a safe and efficacious method for increasing local control of resected spinal metastases (04; 17). In a study of 63 patients with spinal metastases, postoperative radiotherapy resulted in a local control rate of 81% at a median follow-up of 12.5 months; local control rate was significantly improved by preoperative embolization and radiotherapy less than 40 days after surgical intervention (17).

Cancer immunotherapy is a rapidly developing and wide-reaching treatment strategy for local and metastatic cancer patients. As this field advances, it will undoubtedly converge with radiotherapy. Timing of immuno- and radiotherapy and indications for each treatment modality will continue to change as further knowledge regarding how these treatments interact emerges. The role of adaptive immunity in immunotherapy raises the possibility that radiotherapy could locally interact with the immune system by triggering the local production of inflammatory cytokines and release of tumor antigens. Radiotherapy may, therefore, have an important role in local treatment as a component of a systemic treatment strategy when combined with immunotherapy. Preclinical and early clinical studies are examining the safety and efficacy of local radiotherapy dosing, fractionation, and timing in combination with systemic immunotherapy (03).

To be considered candidates for radiosurgery, patients should have an established pathological diagnosis with a clearly visible lesion on radiographic imaging to facilitate accurate targeting of the lesion. Lesions with diameters of 4.5 to 5 cm have been treated by CyberKnife in staged procedures. However, most centers consider 2.5 to 3.0 cm to be the upper limit of radiosurgical treatment size. The proximity of the lesion to critical nervous system structures such as the anterior visual pathways, vestibulocochlear nerve, brain stem, and spinal cord must be taken into consideration when evaluating a lesion for treatment with stereotactic radiosurgery, as it may affect the dosage that can be delivered safely.

Contraindications

The principal contraindication to stereotactic radiosurgery is lesion diameter greater than 2.5 to 3.0 cm because radiation-induced complications increase rapidly with larger volumes treated. Major contraindications to stereotactic radiosurgery include the following:

(1) The tissue diagnosis is uncertain.
(2) Lesion diameter is greater than 3 cm, or multiple lesions have a significantly larger total volume.
(3) Lesion margins are poorly defined.
(4) Proximity to eloquent nervous tissue (eg, optic nerves, vestibulocochlear nerves, brainstem, spinal cord) that cannot tolerate the penumbra radiation dose.

Results

Assuming a competent planning team and stereotactic radiosurgery system, a good outcome depends primarily on the lesion’s sensitivity to radiation, shape, and location (ie, proximity to critical structures).

Brain metastases. Tumor stabilization or reduction occurs in 75% to 90% of cases (160; 64). A meta-analysis of 32 retrospective studies found that treatment of brainstem metastases with a median of 16 Gy resulted in an 86% local control rate with 2.4% treatment-related grade 3 to 5 toxic effects (30). Using mono-isocentric, non-coplanar, LINAC-based stereotactic technique minimizes the amount of radiation to healthy brain tissue, allowing for the safe and efficacious treatment of multiple brain metastases (65; 05). Hypofractionated radiosurgery was found favorable compared to single-fraction radiosurgery for lesions larger than 3 cm (45). Another analysis found both a reduction in radiation necrosis and an improvement in 1-year local control for hypofractionated versus single-fraction radiosurgery (97). A pooled analysis of the literature found lesions with a diameter smaller than 20 mm exhibited excellent 1-year local control rates, over 85%, with a single dose of radiation (18 Gy) (142). However, medium (20-30 mm) and large (> 30 mm) tumors had lower local control rates with such a small dose. As such, they may benefit from fractionated treatments to provide a higher dose without increased rates of radiation necrosis (117; 142). In the treatment of the resection cavity of brain metastases, adding a 2-mm margin improves local control without increasing toxicity and avoids whole-brain radiation (33). In a secondary analysis of a randomized controlled trial, radiosurgery was noted to have improved early local control relative to surgical resection, but the relative benefit lessened over time (36).

Spine metastasis. Efficacy has been demonstrated at all levels of the spine, with cervical spine localization referenced to skull base landmarks and thoracic and lumbosacral spine localization referenced to percutaneously placed fiducials (51). Patients with benign spinal tumors, such as meningiomas, neurofibromas, and schwannomas, were found to have comparable control rates relative to their intracranial counterparts (32). Radiosurgery combined with open surgery (vertebroplasty or kyphoplasty) has been utilized to successfully treat spinal cord compression as a result of metastasis (147). Treatment with a single dose of 12 to 24 Gy resulted in adequate control of local progression in spinal metastases with epidural cord compression (84). In an analysis of 54 patients treated with a median of 24 Gy in 3 fractions, local failure occurred in only 8% with a mean follow-up of 14.36 months, and pain improvement was seen in 76% (91). Metastases to the sacral spine had lower rates of local control and pain improvement than metastases to the thoracolumbar spine (90). A review of 67 studies found that single-fraction stereotactic body radiation therapy, whether performed preoperatively or postoperatively, resulted in 1- and 2-year local control rates of 71% to 95% and 70% to 96%, respectively (58). A majority (85%) of the lesions treated with single-fraction stereotactic body radiation therapy experienced partial or complete pain relief. Stereotactic body radiation therapy was also found to have an acceptable risk profile, as vertebral column fractures and radiation-induced myelopathies occurred in only 6% to 36.1% and in 0 to 10.8% of patients, respectively. In long-term follow-up, increased cumulative dose and point dose to the spinal cord or cauda equina was associated with late toxicity. Vertebral compression fractures were the most common and were observed in 17% of patients at both 5 and 10 years after treatment (105). However, patients who took antiresorptive agents, such as bisphosphonates, before stereotactic body radiation therapy had only a 4% risk of vertebral compression fractures 2 years after radiation, indicating this may be helpful to mitigate the risk of vertebral compression fractures after stereotactic body radiation therapy (134). Schaub and colleagues provide a review of literature that defines toxicity endpoints and actionable dosimetric guidelines to limit toxicity secondary to radiosurgery of the spine (154).

Vestibular schwannoma. Tumor stabilization or reduction occurs in more than 90% of cases (108; 63; 163; 76). In patients who underwent repeat stereotactic radiosurgery for recurrent tumors, tumor control rates at 2, 5, and 10 years were 98.6%, 92.2%, and 92.2%, respectively (74). Radiosurgery is ideal for small- and medium-sized vestibular schwannomas (106; 54). For larger tumors, surgical resection should be performed prior to radiosurgery, with a goal of reducing tumor volume to less than 6 cm³. However, in patients with larger tumors without life-threatening or debilitating symptoms, a stereotactic radiosurgery dose below 13 Gy without surgery was a safe and effective treatment for tumor control (127; 136). Tumor control rates of 92%, 91%, and 91% at 5, 10, and 15 years after radiosurgery were observed in a review of 618 patients (49). In the same study, hearing preservation rates of 53%, 34%, and 34% at 5, 10, and 15 years after radiosurgery were observed (49). In a series of 871 patients, hearing preservation rates were 89.8% at 1 year, 76.9% at 3 years, 68.4% at 5 years, 62.5% at 7 years, and 51.4% at 10 years after radiosurgery (76). Hearing preservation is correlated with the protection of the cochlea from radiation (68); tumor margin doses lower than 12 Gy and cochlear doses lower than 4 Gy maximize hearing preservation (167). Decreased rates of hearing preservation were associated with increased tumor size (23; 153) and the diagnosis of neurofibromatosis 2 (153).

Meningioma. The International Stereotactic Radiosurgery Society recommends stereotactic radiosurgery as an effective treatment for grade 1 meningiomas (111). In a review of studies of large intracranial meningiomas treated with stereotactic radiosurgery, radiographic tumor control ranged from 84% to 100% at follow-up of 2 to 7.5 years (48). However, only 45.1% showed clinical improvement; a two-fold increase in likelihood of improvement was found in non-single-session stereotactic radiosurgery versus single-session stereotactic radiosurgery (OR 2.47) (48). In the treatment of 37 patients with asymptomatic skull base meningiomas with single-session Gamma Knife radiosurgery, tumor size decreased, and there was no mortality caused by either the tumor or the procedure for a mean follow-up of 58.5 months (135). A review of 722 cases found that 94.8% of patients with petroclival meningioma exhibited tumor control following stereotactic radiosurgery, while having 5- and 10-year progression-free survival rates of 91% to 100% and 69.6% to 89.9%, respectively (14). Asymptomatic meningioma patients receiving stereotactic radiosurgery were found to have a tumor control rate of 99.4%, whereas conservatively managed patients had a rate of 62.1%. Importantly, stereotactic radiosurgery was not associated with an increased risk of developing new neurologic deficits (157). Similarly, intraventricular meningiomas were found to respond well to stereotactic radiosurgery; a small study of 11 patients found that 100% of tumors were locally controlled and 55% of tumors decreased in size (173). Radiosurgery may also be an effective treatment option for radiation-induced meningiomas (72).

Arteriovenous malformation. The International Stereotactic Radiosurgery Society cautiously recommends stereotactic radiosurgery as a safe and effective treatment for grade 1 to 2 arteriovenous malformations, particularly in deep or eloquent regions, based on analysis of 1102 arteriovenous malformations in which total obliteration without hemorrhage was achieved in 78% (56). Overall, radiosurgery reduces the risk of arteriovenous malformation hemorrhage, although the benefit is strongly driven by obliteration (44). Success is inversely proportional to the volume and flow of the arteriovenous malformation, with nearly complete success for arteriovenous malformations less than 1 cm in diameter, 75% to 90% success for lesions 1 to 3 cm in diameter, and 35% to 65% success for larger lesions (158). For very large arteriovenous malformations (larger than 10 cm3), a second radiosurgery or surgical intervention treatment within 3 years from the first may be necessary (187; 189). The use of endovascular embolization prior to stereotactic radiosurgery for arteriovenous malformation is also a controversial topic as there are mixed results on the effect of the combined treatments on obliteration (28; 75; 186; 47; 66). For patients with similar arteriovenous malformations, surgical resection and radiosurgery demonstrate similar rates of deficit-free obliteration. Obliteration of the arteriovenous malformation nidus was more frequently achieved with surgery but at the risk of increased new permanent neurologic deficit (29). Long-term obliteration rates with radiosurgery appear to be good as well; the 5- and 10-year nidus obliteration rates were 63% and 82%, respectively, in a large cohort of over 1200 patients (67). The annual hemorrhage rate was 1.5% for the first 5 years and 0.5% after that. Surgical treatment of an arteriovenous malformation frontloads the hemorrhage control and risk of neurologic deficit to the postoperative period, whereas risk of neurologic deficit after radiosurgery can be delayed. Incidence rates of adverse radiation effect at 10 and 15 years after treatment were 4.2% and 10.6%, respectively, so long-term care is necessary (67). In a review of eight studies of spinal arteriovenous malformations treated with 18 to 21 Gy over 2 to 4 fractions, good outcomes were seen in 92.2% with no post-treatment hemorrhage over an average follow-up period of 46.8 months (190).

Dural arteriovenous fistulas. In the treatment of 124 low-risk and 73 high-risk cases of dural arteriovenous fistulas, stereotactic radiosurgery was found to be a safe option with few complications (168). A cohort of 114 patients was treated with a mean margin dose of 21.8 Gy, resulting in obliteration rates of 41.3%, 61.1%, 70.1%, and 82.0% at 3, 5, 7, and 10 years, respectively (162). In a study of 131 patients, cavernous sinus arteriovenous fistulas were more likely to be obliterated than noncavernous sinus fistulas (OR = 4.189) (71). A review of 705 patients with dural arteriovenous fistulas receiving treatment found the complete obliteration rate to be 68.6%, with symptom improvement in 97.2% of patients (159). Fistulas that were not associated with the cavernous sinus and higher grade were less likely to have their symptoms respond to radiosurgery.

Hemangioblastomas. A quantitative meta-analysis of 14 studies of stereotactic radiosurgery use for CNS hemangioblastomas showed an 88.4% 5-year progression-free survival (132). In a large international study of 517 participants with a mean target volume of 0.2 to 0.7 cm3, local tumor control rate after stereotactic radiosurgery was 92% at 3 years, 89% at 5 years, and 79% at 10 years (188). A cohort of 15 patients with 101 lesions was treated with Gamma Knife stereotactic radiosurgery with a median pretreatment volume of 28 mm3 and a median marginal dose of 17.8 Gy. Ninety-seven percent of patients were free from new hemangioblastoma formation at 1 year, 80% at 3 years, and 46% at 5 years. Local failure occurred in only 4% of the treated lesions (103).

Pituitary adenomas. The International Stereotactic Radiosurgery Society recommends stereotactic radiosurgery as an effective and safe treatment for nonfunctional pituitary adenomas based on a meta-analysis of 27 studies that found 5- and 10-year random effects local control estimates after stereotactic radiosurgery (average 15.0 Gy) of 94% and 83%, respectively (88). Post-stereotactic radiosurgery panhypopituitarism occurred in 21% (88). Stereotactic radiosurgery has also been used to treat patients with acromegaly, with low-dose radiosurgery to 15.8 Gy leading to remission in 43.4% of 76 patients treated (130). Another study found similar endocrine remission in acromegaly with 83.3% local tumor control in 21 patients treated (06). In a separate meta-analysis of residual or recurrent tumor control, stereotactic radiosurgery with a mean radiation marginal dose of 19.6 Gy resulted in 95% overall tumor control and 67% hormonal control in secreting tumors, with few side effects (69). A meta-analysis found that stereotactic radiosurgery achieved tumor control in 97%, 92%, and 93% of cases of acromegaly, Cushing disease, and prolactinomas, respectively (114). However, endocrine remission was found in only 44%, 48%, and 28% of patients, respectively.

Chordoma and chondrosarcoma. Stereotactic radiosurgery is currently used in both primary tumor management of small tumors and restricting local progression following surgery (174; 79). A review of the National Cancer Database of 1478 patients with skull base, sacral, or mobile spine chordoma showed a 5-year survival rate of 82.3% with surgical resection and adjuvant radiotherapy versus 70.6% for surgical resection alone in patients with positive tumor margins; stereotactic radiosurgery resulted in higher survival rates than traditional external beam radiation therapy. There was no survival benefit in patients with negative margins (43). Long-term studies utilizing stereotactic radiosurgery with a mean marginal dose of 17 Gy found 5- and 10-year progression-free survival rates of 54.7% and 34.7%, respectively. Age greater than 65 at the time of stereotactic radiosurgery and presence of neurologic deficits before stereotactic radiosurgery were associated with lower local tumor control (137). Tumor volume also likely plays a role; patients with chordoma volumes less than 7 cm³ had significantly longer overall survival rates following gamma knife radiosurgery (22). Preoperative stereotactic body radiation therapy is also promising as all patients receiving preoperative stereotactic body radiation therapy before en bloc resection had negative margins (31).

High-grade glioma. The use of stereotactic radiosurgery in glioma is controversial. The standard treatment of high-grade gliomas includes surgical resection, external beam radiation, and adjuvant temozolomide. Most patients experience tumor progression within the initial tumor margin, and there is no standard treatment for this recurrence. For those who cannot undergo redo resection, stereotactic radiosurgery has been used for the treatment of small volume recurrence or poor surgical candidacy. Results are varied, presumably because of the infiltrative nature of gliomas; however, with refinements in targeted molecular agents, there may be a role for radiosurgery in the treatment of recurrent high-grade gliomas (15; 116). A completed randomized, controlled trial of the addition of stereotactic radiosurgery to conventional radiation and chemotherapy versus conventional radiation and chemotherapy alone did not improve outcome, quality of life, or cognitive function (161). A major cause of disease progression was beyond local failure outside of the stereotactic radiosurgery target in one single-center retrospective study (34). On the other hand, a phase 1 trial of stereotactic radiosurgery with bevacizumab in patients with recurrent glioblastoma using higher doses of stereotactic radiosurgery than the prior study, including only nine patients, demonstrated a median progression-free survival of 7.5 months and overall survival of 13 months, consistent with prior retrospective and prospective studies stating that stereotactic radiosurgery benefits treatment of high-grade gliomas (16; 01; 151). There is increasing interest in the use of stereotactic radiosurgery alongside immunotherapy (169). In a phase I clinical trial, 32 patients with recurrent high-grade gliomas were treated with bevacizumab, an anti PD-1 antibody, and hypofractionated stereotactic radiosurgery; progression-free survival was 7.9 months, and overall survival was 13.4 months (148). Use of stereotactic radiosurgery as a multimodal treatment for these heterogenous and complex high-grade tumors may be an ideal option in the future. Use of preoperative stereotactic radiosurgery is currently under investigation (98). The use of stereotactic radiosurgery and hyperfractionated radiosurgery for the treatment of newly diagnosed and recurrent glioblastoma has generated interest in the field despite the lack of prospective data (156). Overall, the use of stereotactic radiosurgery has been controversial in the treatment of primary or recurrent glioma because data on outcome improvement have been mixed.

Low-grade glioma. In regards to low-grade gliomas, safe surgical resection is the first choice of treatment, but stereotactic radiosurgery has been used for lesions that are too deep to access, particularly pilocytic astrocytomas and grade 2 astrocytomas. For pilocytic astrocytomas, stereotactic radiosurgery was used in both adults and children as postoperative adjuvant and in recurrent or unresectable lesions. Progression-free survival at 1, 3, and 5 years was 84%, 32%, and 32%, respectively, for adult patients with stereotactic radiosurgery, and those who underwent surgical resection had better outcomes (77). In pediatric patients, the progression-free survival was 92%, 83%, and 71% at 1, 3, and 5 years, respectively, with better outcomes in those with small residual solid tumors (78). Long-term progression-free survival in 44 patients receiving stereotactic radiosurgery for juvenile pilocytic astrocytomas at 1, 5, and 10 years was 95.4%, 79%, and 61.4%, respectively (180). In grade 2 astrocytomas, tumor control rates were 67% to 92% with stereotactic radiosurgery in single-center retrospective studies, with up to 41% noted to have radiation-related edema (82; 59; 179). Stereotactic radiosurgery may be an alternative or supplement to surgery in deep or difficult to access locations for these low-grade gliomas.

Other indications. Indications for stereotactic radiosurgery have continued to expand. Studies have demonstrated the utility of stereotactic radiosurgery for a variety of conditions. In a retrospective study consisting of 73 patients with medically refractory essential tremor, Gamma Knife thalamotomy was performed with a median central dose of 140 Gy (range, 130-150) (126). Overall, 93.2% of patients showed improvement in tremor with 60.3% reporting tremor cessation or barely perceptible tremor. Martinez Moreno and colleagues retrospectively analyzed the use of Gamma Knife radiosurgery (86.5 Gy [range: 80-90 Gy]; median: 90 Gy) in 117 patients with medically refractory trigeminal neuralgia (112). The pain-free rate without medications at 3, 5, and 7 years was 85%, 81%, and 76% of patients. Compared to microvascular decompression surgery, stereotactic radiosurgery was found to be less effective than surgery for increasing pain-free intervals (177; 102). Although the use of stereotactic radiosurgery for the treatment of glossopharyngeal neuralgia has not been extensively investigated, some studies suggest that it may be a safe and effective option (138; 18). A meta-analysis found that it had a lower incidence of pain relief but also a lower rate of complications than nerve section (107). Stereotactic radiosurgery resulted in pain reduction when a dose of 75 Gy or higher was used, but long-term rates of pain relief were less promising (13). Radiosurgery has also been compared to open surgical resection of the anterior temporal lobe for the treatment of mesial temporal sclerosis. Although surgery demonstrated an advantage in terms of proportion of seizure remission (78% vs. 52%), radiosurgery also appears to be safe and effective as an alternative for patients who are unable to undergo open surgery (10). In the treatment of epilepsy-causing hypothalamic hamartomas, radiosurgery is a safe and efficacious alternative to open microsurgery (19).

Adverse effects

Adverse reactions to stereotactic radiosurgery can be defined as acute (days), early (weeks to months), or late (> 3 months). Both acute and early reactions are usually self-limiting with no permanent neurologic injury.

Nausea and vomiting are common acute reactions after treatment of posterior fossa lesions, with symptoms occurring in 10% to 16% of patients within 6 hours of treatment. Pretreatment with antiemetics and steroids is useful in minimizing or preventing these symptoms.

Much of the pathology treated with stereotactic radiosurgery has an inherent seizure association. After stereotactic radiosurgery, the risk for seizure is probably elevated for the first 48 hours. Maintenance of therapeutic levels of appropriate antiepileptic drugs is recommended to prevent seizures during the immediate post-treatment period. Further complications that may occur include vertigo, paresthesias, and trigeminal neuralgia (24).

Late reactions to radiosurgery are associated with variable degrees of transient and permanent neurologic sequelae that occur 6 to 9 months after treatment and may have visible changes on CT or MRI (95). In normal tissue near the lesion or in the treatment area, the high dose of radiation may cause blood-brain barrier alterations, cytotoxic edema, myelin lesions, atrophy, calcification, cyst formations, thrombosis of regional vessels (generally in the case of tortuous veins, varices, or venous anomalies), and vasculopathy. Tumoral cytotoxic edema in combination with post-treatment edema may create problems with increased intracranial pressure. These often present several months after stereotactic radiosurgery, with evidence of headaches and perilesional edema on neuroimaging studies. Treatment consists of corticosteroids and diuretics. The condition is usually self-limiting but particularly on occasion when large volumes have been treated with stereotactic radiosurgery, these areas may require surgical decompression. Treatment consists of steroids, often requiring a protracted course of 12 months or longer for resolution. Severe cases may require surgical resection of necrotic tissue to reduce mass effect (164). Data from the treatment of arteriovenous malformations suggest that repeat radiosurgery treatments and deep location of a lesion are risk factors for symptomatic radiation-induced changes (73). Finally, pituitary insufficiency is a potential complication of stereotactic radiosurgery for lesions adjacent to the pituitary gland or hypothalamus.

Though rare, radiation-induced vasculopathy may perforate key branches of cerebral vasculature surrounding targets of radiosurgery, such as the middle cerebral artery (83). Visual deficits can be encountered with targeting areas surrounding the post-geniculate visual pathway, but they are relatively rare, with the risk of sustaining a deficit being 3% at 3 years, 5% at 5 years, and 8% at 10 years (20).

Radiation necrosis is another severe, late complication that occurs in 5% to 26% of cases and can result in symptomatic edema and reduced quality of life (40; 175). In the treatment of brain metastasis, radiation necrosis typically appears between 3 and 9 months following stereotactic radiosurgery, although it can appear up to 5.3 years after treatment (50; 152). Increased risk of radiation necrosis is associated with larger tumor diameter, increased radiation dosage, and advanced age (81). Treatment options for radiation necrosis include observation for asymptomatic lesions and steroids, vitamin E, vascular endothelial growth factor inhibitors (bevacizumab), and surgery for symptomatic lesions (26). Steroids are often the first line of treatment, but they result in numerous side effects when taken at high doses for an extended period of time, which may be required in radiation necrosis. Laser interstitial thermal therapy (LITT) has been used to reduce steroid use in patients with symptomatic radiation necrosis (152). Low doses of bevacizumab have been effective at treating symptomatic radiation necrosis after stereotactic radiosurgery. Bevacizumab reduced the radiation necrosis lesion volume and edema while also improving symptoms and neurologic function (101; 181). Additionally, it is important to note that differentiating between tumor progression and radiation necrosis following stereotactic radiosurgery can be very challenging (93). Occasionally tissue sampling is required to differentiate between the two.

Treatment of lesions of the skull base may result in cranial neuropathies. Sensitivity to radiation injury varies among cranial nerves, with the optic nerve being the most sensitive (single-fraction threshold for injury of approximately 800 cGy) (87). However, specific contouring and targeting strategies that avoid the optic nerve and pathways are successful at avoiding this complication. The cochlear and trigeminal nerves are the next most frequently injured nerves.

Malignant transformation or secondary malignancy following stereotactic radiosurgery is rare (115). Transformation of grade 1 meningiomas to high-grade meningioma and new diagnoses of post-radiation glioblastoma, osteosarcoma, and chondrosarcoma following stereotactic radiosurgery have been reported (129; 96; 92). The time from initial radiosurgery to detection of the secondary malignancy ranged from 58 months (glioblastoma) to 14 years (chondrosarcoma). Of 14,168 patients treated with stereotactic radiosurgery for a variety of intracranial pathologies, the cumulative incidence of radiation-associated malignancy was 0.045% over 10 years, which is similar to the risk of independently developing a malignant CNS tumor (183).

Prognosis varies with the pathological diagnosis and neuroanatomical location of the lesion, as discussed above.

Special considerations

Using stereotactic radiosurgery to treat a woman harboring a brain lesion during pregnancy is feasible because, with abdominal protection, the fetal radiation exposure can be limited to less than 1 rad. Thoracolumbar spinal lesions, however, represent a situation where extremely careful stereotactic radiosurgery treatment planning is essential to minimize fetal radiation exposure. Elderly patients harboring brain lesions or cranial neuralgias may be candidates for stereotactic radiosurgery because it carries lower risks compared to surgical alternatives (37; 119; 138). Special considerations should be given in this patient population, however, due to increased risks of neurologic toxicity (119). Discussions on the goals of care and a neurologic assessment should be performed (119).

Clinical vignette

Case 1. A 59-year-old female presented to the neurosurgery clinic with a known diagnosis of invasive lung adenocarcinoma. She developed a severe headache and difficulty with balance 1 month prior to presentation, and work-up demonstrated two new intracranial metastases. She was found to have a dominant 2.6 x 1.8 x 2.2 cm left lateral cerebellar hemisphere lesion with surrounding perilesional edema as well as a much smaller right cerebellar lesion. She was started on dexamethasone, and her symptoms improved. She underwent stereotactic radiosurgery to both lesions, 19 to 22 Gy in a single fraction. Later that same day she underwent craniotomy for tumor resection of the left lateral cerebellar lesion. She tolerated surgery well and was discharged to home on postoperative day 2. Postoperatively, she remained neurologically intact. At her 3-month follow-up, her right cerebellar lesion was no longer present, and a new area of contrast enhancement was seen within the resection cavity. This was favored to represent radiation effects over tumor progression due to imaging characteristics. She continues to be followed by neurosurgery, radiation oncology, and medical oncology as an outpatient.

Left lateral cerebellar enhancing lesion (MRI)

Axial post-contrast MRI prior to treatment, demonstrating left lateral cerebellar enhancing lesion. (Contributed by Dr. Jason A Heth.)
Left lateral cerebellar enhancing lesion (immediate postoperative MRI)

Immediate postoperative axial post-contrast MRI. (Contributed by Dr. Jason A Heth.)
Left lateral cerebellar enhancing lesion (3-month postoperative MRI)

Coronal post-contrast MRI about 3 months after stereotactic radiosurgery and craniotomy, which demonstrates resolution of the tiny right cerebellar lesion and a new left cerebellar nodular enhancement within the resection cavit...

Case 2. A 41-year-old female developed progressive and disabling spastic quadriparesis over 15 years--Brown-Sequard syndrome with significant loss of right-hand function in particular. Spinal arteriogram demonstrated a C2-C3 spinal cord arteriovenous malformation, which had hemorrhaged on three occasions. Due to the intramedullary location of the arteriovenous malformation, the patient was not a good candidate for microsurgical resection or embolization. Initial stereotactic radiosurgery was with the CyberKnife (10 mm collimator, 3 fractions, total peripheral dose 21 Gy). Clinically, the patient steadily improved, in particular her gait and right-hand function. Spinal arteriogram at 3 years post-stereotactic radiosurgery showed 70% obliteration of the arteriovenous malformation. She underwent a second CyberKnife stereotactic radiosurgery (7.5 mm collimator, 2 fractions, 85% isodose line total 15 Gy). MRI at 4 years following initial stereotactic radiosurgery showed continued improvement, which paralleled her clinical course.

Spinal cord intramedullary arteriovenous malformation, preoperative arteriogram

Spinal cord C2-C3 intramedullary arteriovenous malformation in a 41-year-old female. The preoperative cervical arteriogram demonstrates the large arteriovenous malformation that had bled on three occasions with significant neur...
Spinal cord intramedullary arteriovenous malformation, postoperative arteriogram

Spinal cord C2-C3 intramedullary arteriovenous malformation in a 41-year-old female. The cervical arteriogram 3 years following the initial CyberKnife® stereotactic radiosurgery demonstrates 70% reduction in the arteriovenous malf...
Spinal cord intramedullary arteriovenous malformation, postoperative MRI

Spinal cord C2-C3 intramedullary arteriovenous malformation in a 41-year-old female. The cervical MRI 4 years following the initial CyberKnife® stereotactic radiosurgery and 1 year following the second CyberKnife stereotactic radi...

Case 3. A 76-year-old man presented with a 5-year history of progressive hearing loss in the left ear. An MRI revealed a 12 x 15 x 9 mm contrast-enhancing lesion in the cerebellopontine angle that, on close inspection, followed the course of the facial nerve. The lesion did not compress the brainstem and he demonstrated intact facial function. The patient had no history of neurofibromatosis. Over time, the lesion continued to demonstrate a slow, linear growth pattern. The patient was referred for stereotactic radiosurgery and received a total dose of 12 Gy to the 80% isodose surface with a total treatment tumor volume of 1.77 cm3. The patient tolerated the procedure well and the tumor decreased in size on 1-year interval follow-up imaging. He continues to have intact facial function. Central to this case is the recognition that the cerebellopontine angle lesion was likely a facial nerve schwannoma and not a vestibular schwannoma. Open surgical resection would expose the patient to a high risk of facial nerve dysfunction. Although this is also a risk with stereotactic radiosurgery, the patient has not experienced this complication and continues to do well clinically.

Case 4. A 77-year-old woman presented to the emergency room with confusion, difficulty concentrating, and short-term memory loss. An MRI was ordered, which demonstrated a large left frontal parafalcine contrast-enhancing mass with surrounding vasogenic edema most concerning for a meningioma. She underwent a bifrontal craniotomy for tumor resection, which was complicated by significant cerebral edema, necessitating early closure and subtotal resection. Pathology confirmed a grade 1 meningioma. Initially, she did quite well after this surgery and returned to her neurologic baseline. She was observed on an outpatient basis with slow growth of the tumor. About 1 year after surgery, she developed confusion again and was noted to have rapid growth of her meningioma. She returned to the operating room for another gross total resection of her meningioma, which resulted in memory improvement yet again. She was followed on an outpatient basis, and 5 years after her second surgery was noted to have progression of a new enhancing small lesion within the resection cavity. Stereotactic radiosurgery, 12 Gy in one fraction, was recommended given her advanced age. Three years after stereotactic radiosurgery, the size of her meningioma remained stable and she remained neurologically intact.

Left frontal parafalcine homogenously enhancing lesion (MRI)

Contrasted axial MRI obtained for confusion and memory loss demonstrates a large left frontal parafalcine homogenously enhancing lesion concerning for a meningioma. (Contributed by Dr. Jason A Heth.)
Left frontal parafalcine homogenously enhancing lesion (postoperative MRI)

Axial post-contrast MRI immediately after subtotal resection demonstrates debulking of the lesion. (Contributed by Dr. Jason A Heth.)
Growth of left frontal parafalcine meningioma 1 year after resection (MRI)

Outpatient contrasted MRI demonstrates growth of the left frontal parafalcine meningioma prompting a return to the operating room for redo resection. (Contributed by Dr. Jason A Heth.)
Left frontal parafalcine meningioma after second resection (MRI)

Axial post-contrast MRI after second resection of meningioma. (Contributed by Dr. Jason A Heth.)
Left frontal parafalcine meningioma recurrence at 5-year followup (MRI)

Five-year postoperative follow-up contrasted MRI demonstrating regrowth of contrast-enhancing tumor within the operative cavity, indicating recurrence of the meningioma. (Contributed by Dr. Jason A Heth.)
Left frontal parafalcine meningioma stable 3 years after stereotactic radiosurgery (MRI)

Contrasted MRI 3 years after stereotactic radiosurgery demonstrating stability of the left frontal meningioma recurrence. (Contributed by Dr. Jason A Heth.)

Scientific basis

The goal of radiation therapy is to destroy target cells through the delivery of lethal doses of high-power energy. Radiation beams impart energy to all tissues traversed, invariably damaging surrounding nontarget (normal) tissue, resulting in complications such as impaired wound healing, injury to skin, arteries, and the central or peripheral nervous system, and the induction of secondary malignancies.

Stereotactic radiosurgery seeks to deliver a high dose of radiation to the target while minimizing radiation to surrounding normal tissues. A heavy particle beam accurately delivers much of its energy at a depth predictable by Bragg-peak calculations. Gamma Knife stereotactic radiosurgery relies on multiple sources of cobalt 60 high-energy photons, collimated to limit beam divergence, to focus the radiation on a target. In addition to movement of the gantry and the patient, LINAC employs collimated high-energy photons in a series of converging arcs to focus the radiation on a target. Other LINAC techniques include the use of multiple converging shaped beams (“shaped-beam radiosurgery”), intensity-modulated fixed beams (IMRS), and intensity-modulated arc therapy (IMAT).

The frame-based stereotactic radiosurgery techniques generate an isocentric spherical region of high-dose volume (184). Nonspherical or irregularly shaped targets are treated with multiple isocenters. Multiple isocenters create central necrosis of the target, surrounded by a thin intermediate area of less severely damaged tissue (penumbra); the thinner the penumbra, the more accurate the targeting. A sublethal radiation dose causes vascular intima hyperplasia leading to capillary occlusion, allowing for obliteration of arteriovenous malformations and tumor neovascularity (42).

The CyberKnife delivers non-isocentric spherical radiation beams to lesions that are nonspherical in shape. Mounting the LINAC on a robotic arm created an unconstrained delivery system, making the CyberKnife free to generate beams that originate at arbitrary points within the workspace and target arbitrary points within the lesion.

There is no qualitative difference between cobalt 60 gamma radiation and high-energy x-rays, as relative radiobiological efficiency is equivalent in both. Accelerators derive a theoretical advantage from deeper tissue penetration, especially in 10 to 18 MeV. This limits adherence problems of superficial planes, which are characteristic after cobalt 60 therapies. At present, there is no clinical difference between results obtained with either method.

Media

References

01: Abbassy M, Missios S, Barnett GH, et al. Phase I trial of radiosurgery dose escalation plus bevacizumab in patients with recurrent/progressive glioblastoma. Neurosurgery 2018;83(3):385-92. PMID 28973311
02: Adler JR, Chang SD, Murphy MJ, Doty J, Geis P, Hancock SL. The CyberKnife: a frameless robotic system for radiosurgery. Stereotact Funct Neurosurg 1998;69:124-8. PMID 9711744
03: Alexander BM, Brown PD, Ahluwalia MS, et al. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol 2018;19(1):e33-e42. PMID 29304360
04: Alghamdi M, Tseng CL, Myrehaug S, et al. Postoperative stereotactic body radiotherapy for spinal metastases. Chin Clin Oncol 2017;6(Suppl 2):S18. PMID 28917256
05: Alongi F, Nicosia L, Figlia V, et al. Long-term disease outcome and volume-based decision strategy in a large cohort of multiple brain metastases treated with a mono-isocentric linac-based stereotactic radiosurgery technique. Clin Transl Oncol 2021;23:1561-70. PMID 33570720
06: Alonso CE, Bunevicius A, Trifiletti DM, et al. Safety and efficacy of repeat radiosurgery for acromegaly: an international multi-institutional study. J. Neurooncol 2019;145(2):301-7. PMID 31541405
07: Ammirati M, Nahed BV, Andrews D, Chen CC, Olson JJ. Congress of Neurological Surgeons systematic review and evidence-based guidelines on treatment options for adults with multiple metastatic brain tumors. Neurosurgery 2019;84(3):E180-2. PMID 30629219
08: Asher AL, Burri SH, Wiggins WF, et al. A new treatment paradigm: neoadjuvant radiosurgery before surgical resection of brain metastases with analysis of local tumor recurrence. Int J Radiat Oncol 2014;88(4):899-906. PMID 24606851
09: Ashraf MR, Bruza P, Pogue BW, et al. Optical imaging provides rapid verification of static small beams, radiosurgery, and VMAT plans with millimeter resolution. Med Phys 2019;46(11):5227-37. PMID 31472093
10: Barbaro NM, Quigg M, Ward MM, et al. Radiosurgery versus open surgery for mesial temporal lobe epilepsy: the randomized, controlled ROSE trial. Epilepsia 2018;59(6):1198-207. PMID 29600809
11: Barnett GH, Linskey ME, Adler JR, et al. Stereotactic radiosurgery--an organized neurosurgery-sanctioned definition. J Neurosurg 2007;106(1):1-5. PMID 17240553
12: Baschnagel AM, Cartier JL, Dreyer J, et al. Trigeminal neuralgia pain relief after gamma knife stereotactic radiosurgery. Clin Neurol Neurosurg 2014;117:107-11. PMID 24438815
13: Berckemeyer MA, Suarez-Meade P, Carcelen MFV, et al. Current advances in the surgical treatment of glossopharyngeal neuralgia. Neurosurg Rev 2023;46(1):47. PMID 36725770
14: Bin Alamer O, Palmisciano P, Mallela AN, et al. Stereotactic radiosurgery in the management of petroclival meningiomas: a systematic review and meta-analysis of treatment outcomes of primary and adjuvant radiosurgery. J Neurooncol 2022;157(2):207-19. PMID 35301638
15: Binello E, Green S, Germano IM. Radiosurgery for high-grade glioma. Surg Neurol Int 2012;3(Suppl 2):S118-26. PMID 22826815
16: Bir SC, Connor DE Jr, Ambekar S, Wilden JA, Nanda A. Factors predictive of improved overall survival following stereotactic radiosurgery for recurrent glioblastoma. Neurosurg Rev 2015b;38(4):705-13. PMID 25864406
17: Blakaj DM, Palmer JD, Dibs K, et al. Postoperative stereotactic body radiotherapy for spinal metastasis and predictors of local control. Neurosurgery 2021;88(5):1021-7. PMID 33575784
18: Borius PY, Tuleasca C, Muraciole X, et al. Gamma Knife radiosurgery for glossopharyngeal neuralgia: a study of 21 patients with long-term follow-up. Cephalalgia 2018;38(3):543-50. PMID 28952337
19: Bourdillon P, Ferrand-Sorbet S, Apra C, et al. Surgical treatment of hypothalamic hamartomas. Neurosurg Rev 2021;44(2):753-62. PMID 32318922
20: Bowden G, Kano H, Caparosa E, et al. Stereotactic radiosurgery for arteriovenous malformations of the postgeniculate visual pathway. J Neurosurg 2015;122(2):433-40. PMID 25423270
21: Burkon P, Slavik M, Kazda T, et al. Stereotactic body radiotherapy - current indications. Klin Onkol 2019;32(1):10-24. PMID 30894002
22: Cahill J, Ibrahim R, Mezey G, et al. Gamma knife stereotactic radiosurgery for the treatment of chordomas and chondrosarcomas. Acta Neurochir (Wien) 2021;163(4):1003-11. PMID 33608764
23: Carlson ML, Jacob JT, Pollock BE, et al. Long-term hearing outcomes following stereotactic radiosurgery for vestibular schwannoma: patterns of hearing loss and variables influencing audiometric decline. J Neurosurg 2013;118(3):579-87. PMID 23101446
24: Casentini L, Fornezza U, Perini Z, Perissinotto E, Colombo F. Multisession stereotactic radiosurgery for large vestibular schwannomas. J Neurosurg 2015;122:818-24. PMID 25594321
25: Chang SD, Adler JR Jr, Steinberg GK. General and historical considerations of radiation therapy and radiosurgery. In: Winn RH, editor. Youmans Neurological Surgery. 5th ed. Philadelphia: W.B. Saunders, 2003.
26: Chao ST, Ahluwalia MS, Barnett GH, et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys 2013;87(3):449-57. PMID 23790775
27: Chao ST, Dad LK, Dawson LA, et al. ACR-ASTRO practice parameter for the performance of stereotactic body radiation therapy. Am J Clin Oncol 2020;43(8):545-52. PMID 32404596
28: Chen CJ, Ding D, Lee CC, et al. Stereotactic radiosurgery with versus without embolization for brain arteriovenous malformations. Neurosurgery 2021a;88(2):313-21. PMID 33017465
29: Chen CJ, Ding D, Wang TR, et al. Microsurgery versus stereotactic radiosurgery for brain arteriovenous malformations: a matched cohort study. Neurosurgery 2019;84(3):696-708. PMID 29762746
30: Chen WC, Baal UH, Baal JD, et al. Efficacy and safety of stereotactic radiosurgery for brainstem metastases: a systematic review and meta-analysis. JAMA Oncol 2021b;7(7):1033-40. PMID 33983393
31: Chen X, Lo SL, Bettegowda C, et al. High-dose hypofractionated stereotactic body radiotherapy for spinal chordoma. J Neurosurg Spine 2021c;35(5):674-83. PMID 34388713
32: Chin AL, Fujimoto D, Kumar KA, et al. Long-term update of stereotactic radiosurgery for benign spinal tumors. Neurosurgery 2019;85(5):708-16. PMID 30445557
33: Choi CY, Chang SD, Gibbs IC, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol Phys 2012;84(2):336-42. PMID 22652105
34: Choi SW, Cho KR, Choi JW, et al. Pattern of disease progression following stereotactic radiosurgery in malignant glioma patients. J Clin Neurosci 2020;76:61-6. PMID 32312626
35: Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 2013;87(1):46-52. PMID 23778197
36: Churilla TM, Chowdhury IH, Handorf E, et al. Comparison of local control of brain metastases with stereotactic radiosurgery vs surgical resection: a secondary analysis of a randomized clinical trial. JAMA Oncol 2019;5(2):243-7. PMID 30419088
37: Cohen J, Mousavi SH, Faraji AH, et al. Stereotactic radiosurgery as initial surgical management for elderly patients with trigeminal neuralgia. Stereotact Funct Neurosurg 2017;95(3):158-65. PMID 28501876
38: Coutard H. Roentgentherapy of epitheliomas of the tonsillar region, hypopharynx and larynx from 1920 to 1926. Am J Roentgenol 1932;28:313-31.
39: Das S, Faruqi S, Nordal R, et al. A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases. BMC Cancer 2022;22(1):1368. PMID 36585629
40: Dashti SR, Spalding A, Kadner RJ, et al. Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain. J Neurosurg Pediatr 2015;15(1):20-5. PMID 25360851
41: Davis JN, Medbery C, Sharma S, et al. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry. J Radiat Oncol 2015;4(1):55-63. PMID 25774243
42: De Salles AA, Solberg TD, Mischel P, et al. Arteriovenous malformation animal model for radiosurgery: the rete mirabile. AJNR Am J Neuroradiol 1996;17(8):1451-8. PMID 8883640
43: Dial BL, Kerr DL, Lazarides AL, et al. The role of radiotherapy for chordoma patients managed with surgery: Analysis of the National Cancer Database. Spine (Phila Pa 1976) 2020;45(12):E742-51. PMID 32032324
44: Ding D, Chen CJ, Starke RM, et al. Risk of brain arteriovenous malformation hemorrhage before and after stereotactic radiosurgery. Stroke 2019;50(6):1384-91. PMID 31043153
45: Eaton BR, La Riviere MJ, Kim S, et al. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol 2015;123(1):103-11. PMID 25862006
46: Elnahal SM, Kerstiens J, Helsper RS, Zietman AL, Johnstone PA. Proton beam therapy and accountable care: the challenges ahead. Int J Radiat Oncol Biol Phys 2013;85(4):e165-72. PMID 23265572
47: Erickson N, Mooney J, Salehani A, et al. Predictive factors for arteriovenous malformation obliteration after stereotactic radiosurgery: a single-center study. World Neurosurg 2022;160:e529-36. PMID 35077887
48: Fatima N, Meola A, Pollom E, Chaudhary N, Soltys S, Chang SD. Stereotactic radiosurgery in large intracranial meningiomas: a systematic review. World Neurosurg 2019;129:269-75. PMID 31226450
49: Frischer JM, Gruber E, Schöffmann V, et al. Long-term outcome after Gamma Knife radiosurgery for acoustic neuroma of all Koos grades: a single-center study. J Neurosurg 2018:1-10. PMID 29498575
50: Fujimoto D, von Eyben R, Gibbs IC, et al. Imaging changes over 18 months following stereotactic radiosurgery for brain metastases: both late radiation necrosis and tumor progression can occur. J Neurooncol 2018;136(1):207-12. PMID 29098569
51: Gerszten PC, Ozhasoglu C, Burton SA, et al. CyberKnife frameless single-fraction stereotactic radiosurgery for benign tumors of the spine. Neurosurg Focus 2003;14(5):e16. PMID 15669812
52: Gildenberg PL, Tasker RR. Editors. Textbook of Stereotactic and Functional Neurosurgery. New York: McGraw-Hill, 1998:2174.
53: Ginzac A, Dupic G, Brun L, et al. Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial. BMC Cancer 2021;21(1):864. PMID 34320940
54: Goldbrunner R, Weller M, Regis J, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro Oncol 2020;22(1):31-45. PMID 31504802
55: Graber JJ, Cobbs CS, Olson JJ. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the use of stereotactic radiosurgery in the treatment of adults with metastatic brain tumors. Neurosurgery 2019;84(3):E168-70. PMID 30629225
56: Graffeo CS, Sahgal A, De Salles A, et al. Stereotactic radiosurgery for Spetzler-Martin grade I and II arteriovenous malformations: International Society of Stereotactic Radiosurgery (ISRS) practice guideline. Neurosurgery 2020;87(3):442-52. PMID 32065836
57: Guckenberger M, Baus WW, Blanck O, et al. Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlenther Onkol 2020;196(5):417-20. PMID 32211940
58: Guo L, Ke L, Zeng Z, et al. Stereotactic body radiotherapy for spinal metastases: a review. Med Oncol 2022;39(5):103. PMID 35599266
59: Hadjipanayis CG, Niranjan A, TylerKabara E, Kondziolka D, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for well-circumscribed fibrillary grade II astrocytomas: an initial experience. Stereotact Funct Neurosurg 2002;79:13-24. PMID 12677101
60: Hall EJ, Cox JD. Physical and biologic basis of radiation therapy. In: Cox JD, editor. Moss’ Radiation Oncology. 7th ed. St. Louis: Mosby-Year Book, Inc., 1994:3-6.
61: Hamilton T, Dade Lunsford L. Worldwide variance in the potential utilization of Gamma Knife radiosurgery. J Neurosurg 2016;125(Suppl 1):160-5. PMID 27903178
62: Hannan R, Margulis V, Chun SG, et al. Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. Cancer Biol Ther 2015;16(5):657-61. PMID 25800036
63: Hansasuta A, Choi CY, Gibbs IC, et al. Multisession stereotactic radiosurgery for vestibular schwannomas: single-institution experience with 383 cases. Neurosurgery 2011;69(6):1200-9. PMID 21558974
64: Hardee ME, Formenti SC. Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide. Front Oncol 2012;2:99. PMID 22908046
65: Hartgerink D, Swinnen A, Roberge D, et al. LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation. Acta Oncol 2019;58(9):1275-82. PMID 31257960
66: Hasegawa T, Kato T, Naito T, et al. Effect of embolization before stereotactic radiosurgery for brain arteriovenous malformations: a case-control study with propensity score matching. J Neurosurg 2022a;138(4):955-61. PMID 36087321
67: Hasegawa T, Kato T, Naito T, et al. Long-term risks of hemorrhage and adverse radiation effects of stereotactic radiosurgery for brain arteriovenous malformations. Neurosurgery 2022b;90(6):784-92. PMID 35315812
68: Hayden Gephart MG, Hansasuta A, Balise RR, et al. Cochlea radiation dose correlates with hearing loss after stereotactic radiosurgery of vestibular schwannoma. World Neurosurg 2013;80(3-4):359-63. PMID 22484770
69: Heringer LC, Machado de Lima M, Rotta JM, Botelho RV. Effect of stereotactic radiosurgery on residual or relapsed pituitary adenoma: A systematic review and meta-analysis. World Neurosurg 2020;136:374-81.e4. PMID 31899390
70: Hughes RT, McTyre ER, LeCompte M, et al. Clinical outcomes of upfront stereotactic radiosurgery alone for patients with 5 to 15 brain metastases. Neurosurgery 2019;85(2):257-63. PMID 29982831
71: Hung YC, Mohammed N, Kearns KN, et al. Stereotactic radiosurgery for cavernous sinus versus noncavernous sinus dural arteriovenous fistulas: outcomes and outcome predictors. Neurosurgery 2020;86(5):676-84. PMID 31384943
72: Huo M, Laperriere N, van Prooijen M, et al. Efficacy of stereotactic radiosurgery for radiation-induced meningiomas. J Neurooncol 2020;148(2):299-305. PMID 32342330
73: Ilyas A, Chen CJ, Ding D, et al. Radiation-induced changes after stereotactic radiosurgery for brain arteriovenous malformations: a systematic review and meta-analysis. Neurosurgery 2018;83(3):365-76. PMID 29040700
74: Iorio-Morin C, Liscak R, Vladyka V, et al. Repeat stereotactic radiosurgery for progressive or recurrent vestibular schwannomas. Neurosurgery 2019;85(4):535-42. PMID 30189018
75: Jiang Z, Zhang X, Wan X, et al. Efficacy and safety of combined endovascular embolization and stereotactic radiosurgery for patients with intracranial arteriovenous malformations: a systematic review and meta-analysis. Biomed Res Int 2021;2021:6686167. PMID 33954197
76: Johnson S, Kano H, Faramand A, et al. Long term results of primary radiosurgery for vestibular schwannomas. J. Neurooncol 2019;145(2):247-55. PMID 31535315
77: Kano H, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for pilocytic astrocytomas part 1: outcomes in adult patients. J Neurooncol 2009a;95:211-18. PMID 19468691
78: Kano H, Niranjan A, Kondziolka D, et al. Stereotactic radiosurgery for pilocytic astrocytomas part 2: outcomes in pediatric patients. J Neurooncol 2009b;95: 219-29. PMID 19468692
79: Kano H, Niranjan A, Lunsford LD. Radiosurgery for chordoma and chondrosarcoma. Prog Neurol Surg 2019:207-14. PMID 31096236
80: Kayama T, Sato S, Sakurada K, et al. Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (jcog0504): a phase III, noninferiority, randomized controlled trial. J Clin Oncol 2018;JCO2018786186. PMID 29924704
81: Kerschbaumer J, Demetz M, Krigers A, Nevinny-Stickel M, Thomé C, Freyschlag CF. Risk factors for radiation necrosis in patients undergoing cranial stereotactic radiosurgery. Cancers (Basel) 2021;13(19):4736. PMID 34638223
82: Kida Y, Kobayashi T, Mori Y: Gamma KNIFE radiosurgery for low-grade astrocytomas: results of long-term follow up. J Neurosurg 2000;93(suppl 3):42-6. PMID 11143261
83: Kim DH, Kang DH, Park J, Hwang JH, Park SH, Son WS. Delayed perilesional ischemic stroke after gamma-knife radiosurgery for unruptured deep arteriovenous malformation: two case reports of radiation-induced small artery injury as possible cause. J Cerebrovasc Endovasc Neurosurg 2015;17(1):36-42. PMID 25874184
84: Kim YJ, Kim JH, Kim K, et al. The feasibility of spinal stereotactic radiosurgery for spinal metastasis with epidural cord compression. Cancer Res Treat 2019;51(4):1324-35. PMID 30699497
85: Koide Y, Tomita N, Adachi S, Tanaka H, Tachibana H, Kodaira T. Retrospective analysis of hypofractionated stereotactic radiotherapy for tumors larger than 2 cm. Nagoya J Med Sci 2019;81(3):397-406. PMID 31579330
86: Kondziolka D, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for epilepsy and functional disorders. Neurosurg Clin N Am 2013;24(4):623-32. PMID 24093580
87: Kondziolka D, Lunsford LD. Radiosurgery of meningiomas. Neurosurg Clin N Am 1992;3:219-30. PMID 1633448
88: Kotecha R, Sahgal A, Rubens M, et al. Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion. Neuro Oncol 2020;22(3):318-32. PMID 31790121
89: Kotecha R, Tonse R, Menendez MAR, et al. Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. Sci Rep 2022;12(1):4567. PMID 35296750
90: Kowalchuk RO, Waters MR, Richardson KM, et al. A comparison of stereotactic body radiation therapy for metastases to the sacral spine and treatment of the thoracolumbar spine. J Radiosurg SBRT 2020b;7(2):95-103. PMID 33282463
91: Kowalchuk RO, Waters MR, Richardson KM, et al. Stereotactic radiosurgery for the treatment of bulky spine metastases. J Neurooncol 2020a;148(2):381-8. PMID 32415643
92: Lall RR, Lall RR, Smith TR, et al. Delayed malignant transformation of petroclival meningioma to chondrosarcoma after stereotactic radiosurgery. J Clin Neurosci 2014;21(7):1225-8. PMID 24491582
93: Lasocki A, Sia J, Stuckey SL. Improving the diagnosis of radiation necrosis after stereotactic radiosurgery to intracranial metastases with conventional MRI features: a case series. Cancer Imaging 2022;22(1):33. PMID 35794677
94: Lawrence JH, Aebersold PC, Lawrence EO. Comparative effects of x-rays and neutrons on normal and tumor tissue. Proc Natl Acad Sci U S A 1936;22:543-57. PMID 16588107
95: Lee EQ. Nervous system metastases from systemic cancer. Continuum (Minneap Minn) 2015;21(2 Neuro-oncology):415-28. PMID 25837904
96: Lee HS, Kim JH, Lee JI. Glioblastoma following radiosurgery for meningioma. J Korean Neurosurg Soc 2012b;51(2):98-101. PMID 22500202
97: Lehrer EJ, Peterson JL, Zaorsky NG, et al. Single versus multifraction stereotactic radiosurgery for large brain metastases: an international meta-analysis of 24 trials. Int J Radiat Oncol Biol Phys 2019;103(3):618-30. PMID 30395902
98: Lehrer EJ, Ruiz-Garcia H, Nehlsen AD, et al. Preoperative stereotactic radiosurgery for glioblastoma. Biology (Basel) 2022;11(2):194. PMID 35205059
99: Leksell L. Cerebral radiosurgery. Gammathalotomy in two cases of intractable pain. Acta Chir Scand 1968;134:585-95. PMID 5713443
100: Leksell L. The stereotactic method and radiosurgery of the brain. Acta Chir Scand 1951;102:316-9. PMID 14914373
101: Li J, He J, Cai L, et al. Bevacizumab as a treatment for radiation necrosis following stereotactic radiosurgery for brain metastases: clinical and radiation dosimetric impacts. Ann Palliat Med 2021;10(2):2018-26. PMID 33549015
102: Li L, Seaman SC, Bathla G, et al. Microvascular decompression versus stereotactic radiosurgery for trigeminal neuralgia: a single-institution experience. World Neurosurg 2020;143:e400-e8. PMID 32745644
103: Liebenow B, Tatter A, Dezarn WA, Isom S, Chan MD, Tatter SB. Gamma Knife stereotactic radiosurgery favorably changes the clinical course of hemangioblastoma growth in von Hippel-Lindau and sporadic patients. J Neurooncol 2019;142(3):471-8. PMID 30729402
104: Lin B, Gao F, Yang Y, et al. FLASH radiotherapy: history and future. Front Oncol 2021;11:644400. PMID 34113566
105: Ling DC, Flickinger JC, Burton SA, et al. Long-term outcomes after stereotactic radiosurgery for spine metastases: radiation dose-response for late toxicity. Int J Radiat Oncol Biol Phys 2018;101(3):602-9. PMID 29678526
106: Liu W, Ni M, Jia W, et al. How to address small and medium-sized acoustic neuromas with hearing: a systematic review and decision analysis. World Neurosurg 2015;84(2):283-91. PMID 25790873
107: Lu VM, Goyal A, Graffeo CS, Perry A, Jonker BP, Link MJ. Glossopharyngeal neuralgia treatment outcomes after nerve section, microvascular decompression, or stereotactic radiosurgery: a systematic review and meta-analysis. World Neurosurg 2018;120:572-82.e7. PMID 30240868
108: Lunsford LD, Niranjan A, Flickinger JC, Maitz A, Kondziolka D. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg 2005;102:195-9. PMID 15662809
109: Ma L, Wang L, Tseng CL, Sahgal A. Emerging technologies in stereotactic body radiotherapy. Chin Clin Oncol 2017;6(Suppl 2):S12. PMID 28917250
110: Marchan EM, Peterson J, Sio TT, et al. Postoperative cavity stereotactic radiosurgery for brain metastases. Front Oncol 2018;8:342. PMID 30234013
111: Marchetti M, Sahgal A, De Salles AA, et al. Stereotactic radiosurgery for intracranial noncavernous sinus benign meningioma: International Stereotactic Radiosurgery Society systematic review, meta-analysis and practice guideline. Neurosurgery 2020;87(5):879-90. PMID 32463867
112: Martinez Moreno NE, Gutiérrez-Sárraga J, Rey-Portolés G, Jiménez-Huete A, Martínez Álvarez R. Long-term outcomes in the treatment of classical trigeminal neuralgia by Gamma Knife radiosurgery: a retrospective study in patients with minimum 2-year follow-up. Neurosurgery 2016;79(6):879-88. PMID 27560193
113: Mascia AE, Daugherty EC, Zhang Y, et al. Proton FLASH radiotherapy for the treatment of symptomatic bone metastases: the FAST-01 nonrandomized trial. JAMA Oncol 2023;9(1):62-9. PMID 36273324
114: Mathieu D, Kotecha R, Sahgal A, et al. Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and International Stereotactic Radiosurgery Society practice recommendations. J Neurosurg 2021;136(3):801-12. PMID 34479203
115: McIver JI, Pollock BE. Radiation-induced tumor after stereotactic radiosurgery and whole brain radiotherapy: case report and literature review. J Neurooncol 2004;66:301-5. PMID 15015661
116: McKenzie JT, Guarnaschelli JN, Vagal AS, Warnick RE, Breneman JC. Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas. J Neurooncol 2013;113(3):403-9. PMID 23589034
117: Milano MT, Grimm J, Niemierko A, et al. Single- and multifraction stereotactic radiosurgery dose/volume tolerances of the brain. Int J Radiat Oncol Biol Phys 2021;110(1):68-86. PMID 32921513
118: Minniti G, Capone L, Nardiello B, et al. Neurological outcome and memory performance in patients with 10 or more brain metastases treated with frameless linear accelerator (LINAC)-based stereotactic radiosurgery. J Neurooncol 2020;148(1):47-55. PMID 32100230
119: Minniti G, Filippi AR, Osti MF, Ricardi U. Radiation therapy for older patients with brain tumors. Radiat Oncol 2017;12(1):101. PMID 28629376
120: Mitin T, Zietman AL. Promise and pitfalls of heavy-particle therapy. J Clin Oncol 2014;32(26):2855-63. PMID 25113772
121: Mizumoto M, Tsuboi K, Igaki H, et al. Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2010;77(1):98-105. PMID 19695794
122: Montay-Gruel P, Acharya MM, Gonçalves Jorge P, et al. Hypofractionated FLASH-RT as an effective treatment against glioblastoma that reduces neurocognitive side effects in mice. Clin Cancer Res 2021;27(3):775-84. PMID 33060122
123: Nagai A, Shibamoto Y, Yoshida M, Wakamatsu K, Kikuchi Y. Treatment of single or multiple brain metastases by hypofractionated stereotactic radiotherapy using helical tomotherapy. Int J Mol Sci 2014;15(4):6910-24. PMID 24758932
124: Nahed BV, Alvarez-Breckenridge C, Brastianos PK, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the role of surgery in the management of adults with metastatic brain tumors. Neurosurgery 2019;84(3):E152-5. PMID 30629227
125: Nath SK, Lawson JD, Simpson DR, et al. Single-isocenter frameless intensity-modulated stereotactic radiosurgery for simultaneous treatment of multiple brain metastases: clinical experience. Int J Radiat Oncol Biol Phys 2010;78(1):91-7. PMID 20096509
126: Niranjan A, Raju SS, Kooshkabadi A, Monaco E 3rd, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for essential tremor: retrospective analysis of a 19-year experience. Mov Disord 2017;32(5):769-77. PMID 28319282
127: Ogino A, Lunsford LD, Long H, et al. Stereotactic radiosurgery as the primary management for patients with Koos grade IV vestibular schwannomas. J Neurosurg 2021;135(4):1058-66. PMID 33578383
128: Ohye C, Higuchi Y, Shibazaki T, et al. Gamma knife thalamotomy for Parkinson disease and essential tremor: a prospective multicenter study. Neurosurgery 2012;70(3):526-35;discussion 535-6. PMID 21904267
129: Osipov V, Ho KC, Krouwer HG, Meyer G, Shidham VB. Post-radiation dedifferentiation of meningioma into osteosarcoma. BMC Cancer 2002;2:34. PMID 12464160
130: Pai FY, Chen CJ, Wang WH, et al. Low-dose gamma knife radiosurgery for acromegaly. Neurosurgery 2019;85(1):E20-30. PMID 30169716
131: Palmer JD, Perlow HK, Matsui JK, et al. Fractionated pre-operative stereotactic radiotherapy for patients with brain metastases: a multi-institutional analysis. J Neurooncol 2022;159(2):389-95. PMID 35751740
132: Pan J, Jabarkheel R, Huang Y, Ho A, Chang SD. Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis. J Neurooncol 2018;137(1):11-22. PMID 29204841
133: Patel KR, Burri SH, Asher AL, et al. Comparing preoperative with postoperative stereotactic radiosurgery for respectable brain metastases: a multi-institutional analysis. Neurosurgery 2016;79(2):279-85. PMID 26528673
134: Patel PP, Esposito EP, Zhu J, et al. Antiresorptive medications prior to stereotactic body radiotherapy for spinal metastasis are associated with reduced incidence of vertebral body compression fracture. Global Spine J 2023. [Epub ahead of print] PMID 36749660
135: Pikis S, Bunevicius A, Sheehan J. Outcomes from treatment of asymptomatic skull base meningioma with stereotactic radiosurgery. Acta Neurochir (Wien) 2021;163(1):83-8. PMID 33211178
136: Pikis S, Mantziaris G, Kormath Anand R, et al. Stereotactic radiosurgery for Koos grade IV vestibular schwannoma: a multi-institutional study. J Neurosurg 2022a;138(2):405-12. PMID 36303474
137: Pikis S, Mantziaris G, Peker S, et al. Stereotactic radiosurgery for intracranial chordomas: an international multiinstitutional study. J Neurosurg 2022b;1-8. PMID 35120328
138: Pommier B, Touzet G, Lucas C, Vermandel M, Blond S, Reyns N. Glossopharyngeal neuralgia treated by Gamma Knife radiosurgery: safety and efficacy through long-term follow-up. J Neurosurg 2017:1-8. PMID 28621622
139: Prabhu RS, Dhakal R, Vaslow ZK, et al. Preoperative radiosurgery for resected brain metastases: the PROPS-BM multicenter cohort study. Int J Radiat Oncol Biol Phys 2021;111(3):764-72. PMID 34058254
140: Prabhu RS, Miller KR, Asher AL, et al. Preoperative stereotactic radiosurgery before planned resection of brain metastases: updated analysis of efficacy and toxicity of a novel treatment paradigm. J Neurosurg 2018;1-8. PMID 30554174
141: Redmond KJ, De Salles AAF, Fariselli L, et al. Stereotactic radiosurgery for postoperative metastatic surgical cavities: a critical review and International Stereotactic Radiosurgery Society (ISRS) practice guidelines. Int J Radiat Oncol Biol Phys 2021a;111(1):68-80. PMID 33891979
142: Redmond KJ, Gui C, Benedict S, et al. Tumor control probability of radiosurgery and fractionated stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2021b;110(1):53-67. PMID 33390244
143: Regis J, Carron R, Bartolomei F, Chauvel P. Seeking new paradigms in epilepsy: stereotactic radiosurgery. Clin Neurosurg 2012;59:59-69. PMID 22960514
144: Routman DM, Yan E, Vora S, et al. Preoperative stereotactic radiosurgery for brain metastases. Front Neurol 2018;9:959. PMID 30542316
145: Ruggieri R, Naccarato S, Mazzola R, et al. Linac-based VMAT radiosurgery for multiple brain lesions: comparison between a conventional multi-isocenter approach and a new dedicated mono-isocenter technique. Radiat Oncol 2018;13(1):38. PMID 29506539
146: Ryken TC, Meeks SL, Pennington EC, et al. Initial clinical experience with frameless stereotactic radiosurgery: analysis of accuracy and feasibility. Int J Radiat Oncol Biol Phys 2001;51(4):1152-8. PMID 11704340
147: Ryu S, Yoon H, Stessin A, Gutman F, Rosiello A, Davis R. Contemporary treatment with radiosurgery for spine metastasis and spinal cord compression in 2015. Radiat Oncol J 2015;33(1):1-11. PMID 25874172
148: Sahebjam S, Forsyth PA, Tran ND, et al. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neuro Oncol 2021;23(4):677-86. PMID 33173935
149: Sahgal A, Ma L, Chang E, et al. Advances in technology for intracranial stereotactic radiosurgery. Technol Cancer Res Treat 2009a;8(4):271-80. PMID 19645520
150: Sahgal A, Ma L, Tsao M, et al. Gamma Knife radiosurgery. In: Vaezy S, Zderic V, editors. Image-guided therapy systems. Norwood, MA: Artech House, 2009b:161-75.
151: Sallabanda K, Yañez L, Sallabanda M, Santos M, Calvo FA, Marsiglia H. Stereotactic radiosurgery for the treatment of recurrent high-grade gliomas: long-term follow-up. Cureus 2019;11(12):e6527. PMID 31911881
152: Sankey EW, Grabowski MM, Srinivasan ES, et al. Time to steroid independence after laser interstitial thermal therapy vs medical management for treatment of biopsy-proven radiation necrosis secondary to stereotactic radiosurgery for brain metastasis. Neurosurgery 2022;90(6):684-90. PMID 35311745
153: Santa Maria PL, Shi Y, Gurgel RK, et al. Long-term hearing outcomes following stereotactic radiosurgery in vestibular schwannoma patients: a retrospective cohort study. Neurosurgery 2019;85(4):550-9. PMID 30247723
154: Schaub SK, Tseng YD, Chang EL, et al. Strategies to mitigate toxicities from stereotactic body radiation therapy for spine metastases. Neurosurgery 2019;85(6):729-40. PMID 31264703
155: Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol 2007;25(8):953-64. PMID 17350944
156: Shah JL, Li G, Shaffer JL, et al. Stereotactic radiosurgery and hypofractionated radiotherapy for glioblastoma. Neurosurgery 2018;82(1):24-34. PMID 28605463
157: Sheehan J, Pikis S, Islim AI, et al. An international multicenter matched cohort analysis of incidental meningioma progression during active surveillance or after stereotactic radiosurgery: the IMPASSE study. Neuro Oncol 2022;24(1):116-24. PMID 34106275
158: Silander H, Pellettieri L, Enblad P, et al. Fractionated, stereotactic proton beam treatment of cerebral arteriovenous malformations. Act Neurol Scand 2004;109(2):85-90. PMID 14705968
159: Singh R, Chen CJ, Didwania P, et al. Stereotactic radiosurgery for dural arteriovenous fistulas: a systematic review and meta-analysis and International Stereotactic Radiosurgery Society practice guidelines. Neurosurgery 2022;91(1):43-58. PMID 35383682
160: Soltys SG, Adler JR, Lipani JD, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 2008;70(1):187-93. PMID 17881139
161: Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004;60(3):853-60. PMID 15465203
162: Starke RM, McCarthy DJ, Chen CJ, et al. Evaluation of stereotactic radiosurgery for cerebral dural arteriovenous fistulas in a multicenter international consortium. J Neurosurg 2020;132(1):114-21. PMID 30611144
163: Sun S, Liu A. Long-term follow-up studies of Gamma Knife surgery with a low margin dose for vestibular schwannoma. J Neurosurg 2012;117 Suppl:57-62. PMID 23205790
164: Telera S, Fabi A, Pace A, et al. Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease. J Neurooncol 2013;113(2):313-25. PMID 23525948
165: Thompson TP, Maitz AH, Kondziolka D, et al. Radiation, radiobiology, and neurosurgery. Contemp Neurosurg 1999;21(13):1-5.
166: Tobias CA, Anger HO, Lawrence JH. Radiological use of high energy deuterons and alpha particles. Am J Roentgenol 1952;67:1-27. PMID 14903252
167: Tolisano AM, Hunter JB. Hearing preservation in stereotactic radiosurgery for vestibular schwannoma. J Neurol Surg B Skull Base 2019;80(2):156-64. PMID 30931223
168: Tonetti DA, Gross BA, Jankowitz BT, et al. Reconsidering an important subclass of high-risk dural arteriovenous fistulas for stereotactic radiosurgery. J Neurosurg 2018;1-5. PMID 29547086
169: Tsien C. Stereotactic radiation therapy with concurrent immunotherapy for recurrent glioblastoma-hope or hype? Neuro Oncol 2021;23(4):535-6. PMID 33710345
170: Tuleasca C, Carron R, Resseguier N, et al. Patterns of pain-free response in 497 cases of classic trigeminal neuralgia treated with Gamma Knife surgery and followed up for at least 1 year. J Neurosurg 2012;117 Suppl:181-8. PMID 23205808
171: Turcas A, Kelly SM, Clementel E, Cernea D. Tomotherapy for cranio-spinal irradiation. Clin Transl Radiat Oncol 2022;38:96-103. PMID 36407491
172: Udovicich C, Ng SP, Tange D, Bailey N, Haghighi N. From postoperative to preoperative: a case series of hypofractionated and single-fraction neoadjuvant stereotactic radiosurgery for brain metastases. Oper Neurosurg (Hagerstown) 2022;22(4):208-14. PMID 35234410
173: Umekawa M, Shinya Y, Hasegawa H, Katano A, Saito N. Primary stereotactic radiosurgery provides favorable tumor control for intraventricular meningioma: a retrospective analysis. J Clin Med 2023;12(3):1068. PMID 36769714
174: Van Gompel JJ, Janus JR. Chordoma and chondrosarcoma. Otolaryngol Clin North Am 2015;48(3):501-14. PMID 25863568
175: Vellayappan BA, McGranahan T, Graber J, et al. Radiation necrosis from stereotactic radiosurgery-how do we mitigate? Curr Treat Options Oncol 2021;22(7):57. PMID 34097171
176: Vulpe H, Save AV, Xu Y, et al. Frameless stereotactic radiosurgery on the Gamma Knife Icon: early experience from 100 patients. Neurosurgery 2020;86(4):509-16. PMID 31375826
177: Wang DD, Raygor KP, Cage TA, et al. Prospective comparison of long-term pain relief rates after first-time microvascular decompression and stereotactic radiosurgery for trigeminal neuralgia. J Neurosurg 2018;128(1):68-77. PMID 28298026
178: Wang L, Kielar K, Mok E, Hsu A, Dieterich S, Xing L. An end-to-end examination of geometric accuracy of IGRT using a new digital accelerator equipped with onboard imaging system. Phys Med Biol 2012;57(3):757-69. PMID 22252134
179: Wang LW, Shiau CY, Chung WY, et al. Gamma Knife surgery for low-grade astrocytomas: evaluation of long-term outcome based on a 10-year experience. J Neurosurg 2006;105(suppl):127-32. PMID 18503345
180: Wei Z, Pease M, Tang LW, et al. Radiosurgery outcomes in infratentorial juvenile pilocytic astrocytomas. J Neurooncol 2023;162(1):157-65. PMID 36894718
181: Weng Y, Shen J, Zhang L, et al. Low-dosage bevacizumab treatment: effect on radiation necrosis after gamma knife radiosurgery for brain metastases. Front Surg 2021;8:720506. PMID 34540887
182: Winston KR, Lutz W. Linear accelerator as a neurosurgical tool for stereotactic radiosurgery. Neurosurgery 1988;22:454-64. PMID 3129667
183: Wolf A, Naylor K, Tam M, et al. Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study. Lancet Oncol 2019;20(1):159-64. PMID 30473468
184: Wu A. Physics and dosimetry of the gamma knife. Neurosurg Clin North Am 1992;3:35-50. PMID 1633451
185: Xu AY, Wang YF, Wang TJC, et al. Performance of the cone beam computed tomography-based patient positioning system on the Gamma Knife Icon™. Med Phys 2019;46(10):4333-9. PMID 31359438
186: Yan D, Chen Y, Li Z, et al. Stereotactic radiosurgery with vs. without prior embolization for brain arteriovenous malformations: a propensity score matching analysis. Front Neurol 2021;12:752164. PMID 34712200
187: Yamamoto M, Akabane A, Matsumaru Y, Higuchi Y, Kasuya H, Urakawa Y. Long-term follow-up results of intentional 2-stage Gamma Knife surgery with an interval of at least 3 years for arteriovenous malformations larger than 10 cm3. J Neurosurg 2012;117 Suppl:126-34. PMID 23205800
188: Yamazaki H, Ogita M, Himei K, et al. Carotid blowout syndrome in pharyngeal cancer patients treated by hypofractionated stereotactic re-irradiation using CyberKnife: a multi-institutional matched-cohort analysis. Radiother Oncol 2015;115(1):67-71. PMID 25827266
189: Zaidi HA, Abla AA, Nakaji P, Spetzler RF. Prospective evaluation of preoperative stereotactic radiosurgery followed by delayed resection of a high grade arteriovenous malformation. J Clin Neurosci 2014;21(6):1077-80. PMID 24472236
190: Zhan PL, Jahromi BS, Kruser TJ, Potts MB. Stereotactic radiosurgery and fractionated radiotherapy for spinal arteriovenous malformations: a systematic review of the literature. J Clin Neurosci 2019;62:83-7. PMID 30678835

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Jason A Heth MD

Dr. Heth of the University of Michigan has no relevant financial relationships to disclose.
See Profile
Lisa M Walsh BS

Ms. Walsh of the University of Michigan has no relevant financial relationships to disclose.
See Profile
Katherine Holste MD

Dr. Holste of the University of Michigan has no relevant financial relationships to disclose.
See Profile

Editor

Matthew Lorincz MD PhD

Dr. Lorincz of the University of Michigan has no relevant financial relationships to disclose.
See Profile

Former Authors

David B Altshuler MD
Yoshie Umemura MD
Clare M Wieland
Osvaldo Betti (original author), Arnett Klugh III, Steven D Chang, Robert N Sinha MD, Russell J Andrews MD, Melanie Hayden Gephart MD MAS, Eli Johnson BS, Ian Connolly MS, Vinod Ravikumar BS, Allen Ho MD, Kevin Kwong-Hon Chow MD, and Patrick Swift MD

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Stereotactic radiosurgery

Also Relevant

Brain metastases
Brain metastases: considerations for surgical and radiosurgical treatment
Hemangioblastoma
Meningiomas
Pituitary adenoma
- Radiation myelopathy
- Stereotactic neurosurgery

Clinical Categories

General Neurology

Stereotactic radiosurgery

Stereotactic radiosurgery

Introduction

Overview

Key points

Historical note and terminology

Clinical aspects

Description

Indications

Contraindications

Results

Adverse effects

Special considerations

Clinical vignette

Scientific basis

Media

References

Contributors

Authors

Editor

Former Authors

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Toxic and nutritional deficiency optic neuropathies

Third nerve palsy

Nystagmus

Brain death/death by neurologic criteria

Outpatient rehabilitation of chronic neurologic conditions

Stereotactic radiosurgery

Introduction

Overview

Key points

Historical note and terminology

Clinical aspects

Description

Indications

Contraindications

Results

Adverse effects

Special considerations

Clinical vignette

Scientific basis

Media

References

Contributors

Authors

Editor

Former Authors

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Toxic and nutritional deficiency optic neuropathies

Third nerve palsy

Nystagmus

Brain death/death by neurologic criteria

Outpatient rehabilitation of chronic neurologic conditions

This is an article preview.
Start a Free Account
to access the full version.